The Real Cost of Medicine Is Not Just Price, It Is Distance

Hatched by Gerold

Jun 17, 2026

10 min read

3 views

76%

What if the most expensive part of health care is not the treatment itself?

A person can live in a world where a medicine exists, a diagnosis is possible, and a cure is technically available, yet still never receive care. That is the hidden scandal inside modern health systems: the problem is often not only that care is expensive, but that expensive care behaves like a wall. It rises between a patient and the possibility of survival, then quietly turns illness into a lottery.

That wall matters everywhere, but it becomes especially brutal when a disease is common, chronic, and underdiagnosed. Now imagine that same wall in places where millions of people are already living with illness they do not even know they have. The result is a cruel paradox: the more common the disease, the more invisible it can become, and the more expensive the treatment, the less likely people are to reach it in time.

This is not just a story about health care pricing. It is a story about access as a form of geography. Who gets diagnosed? Who gets treated? Who gets counted? And who is excluded long before the bill ever arrives?

The true unit of scarcity is not medicine, but reach

When a drug price rises from nearly 18,000 dollars a year to more than 52,000 dollars, the number on the invoice tells only part of the story. The deeper issue is that high prices do not simply make care expensive. They narrow the radius of care. A therapy may exist in the abstract, but its practical availability shrinks to the point where only a small fraction of people can touch it.

This is why expensive medicine behaves differently from expensive luxury goods. If a watch is overpriced, many people walk away. If a life saving drug is overpriced, people do not merely walk away. They delay, ration, borrow, skip refills, or never seek care at all. In that sense, price is not just a market outcome. It is a public health mechanism that shapes who lives long enough to benefit from medicine in the first place.

Now bring in chronic disease prevalence, especially in countries where large populations live with diabetes and nearly half may be undiagnosed. A disease that is both common and hidden creates a dangerous illusion. It seems less urgent because it is less visible, and it becomes less visible because the health system is too weak or too costly to find it early. The disease spreads quietly, then arrives late, then becomes expensive, then becomes harder still to treat. That is the vicious circle.

The important insight is this: a health system can fail not only by providing too little care, but by making care too expensive to detect disease early enough. In other words, cost does not just affect treatment. It affects epidemiology itself.

When care is expensive, illness does not disappear. It simply moves deeper underground.

Why diabetes reveals the logic of expensive care

Diabetes is useful as a lens because it sits at the intersection of prevalence, invisibility, and long term cost. Unlike an acute illness with dramatic symptoms, diabetes often develops quietly. People can live for years without knowing they have it, especially where routine screening is inconsistent and access to primary care is uneven. By the time symptoms become obvious, damage may already be underway.

This is where the economics of health care become morally revealing. A system that prices care too high tends to reward late intervention over early detection. It is easier to pay for dramatic rescue than for quiet prevention, even though prevention is usually cheaper and far more humane. That is backwards, but it is common.

Think of it like a house fire. It is far more expensive to rebuild after the roof collapses than to install and maintain smoke alarms. Yet many health systems behave as though the alarm is optional and the fire brigade is the real solution. For diabetes, that means we often wait until the person has complications, then deploy insulin, emergency care, dialysis, wound treatment, eye care, or amputations. Those costs are not just financial. They are humanly catastrophic.

What makes diabetes especially useful as a case study is that it exposes how two separate failures multiply each other:

Detection failure: millions are undiagnosed.
Affordability failure: diagnosis does not guarantee access to continuous care.

Together, they create a pipeline from silence to suffering. A person who does not know they are ill cannot seek treatment. A person who knows but cannot afford treatment may be functionally trapped anyway. The health system then records the damage instead of preventing it.

This is why comparing disease prevalence alone to drug pricing alone misses the larger point. The real issue is the distance between need and care. High prices stretch that distance. Underdiagnosis hides it. And chronic disease converts it into years of avoidable harm.

The hidden architecture of exclusion

Most people think of health care cost as a simple transaction problem: medicine costs too much, so people cannot pay. But that is only the surface layer. Below it is an architecture of exclusion built from many small frictions, each one seemingly minor, each one devastating in combination.

A patient may need to travel to a clinic. The clinic may not have testing supplies. The diagnosis may be delayed. The doctor may prescribe a medicine the pharmacy does not stock. The available version may be unaffordable. The patient may have to choose between the drug and food. If the person does start treatment, follow up may be inconsistent. If complications emerge, the next level of care may be even more inaccessible.

None of these barriers alone looks like a catastrophe. Together, they become a machine that filters people out.

This is the part of the conversation that matters most: high prices are not isolated problems, they are amplifier problems. They amplify every weakness already present in the system. A strong primary care network can absorb some cost pressure. A weak one cannot. A nation with widespread insurance coverage can blunt the shock of expensive drugs. A nation without it turns price into abandonment.

Specialty drugs tripling in price over a decade is alarming not just because the number is big, but because it signals an economy in which innovation, patent power, provider pricing, and market opacity can drift far away from patient reality. The more complex the drug market becomes, the more ordinary people become spectators in their own survival. And when that happens, health care stops behaving like a public good and starts behaving like a gated asset class.

For countries facing large burdens of chronic disease, especially where a big share remains undiagnosed, this is more than an American or Nigerian issue. It is a global warning. When a system cannot reliably identify the sick and cannot afford to treat them, it does not merely have a cost problem. It has a coordination problem between biology and institutions.

A better framework: the three gaps between illness and recovery

To understand why expensive care and hidden disease reinforce each other, it helps to use a simple framework: the three gaps.

1. The diagnosis gap

This is the distance between being ill and knowing it. In diseases like diabetes, this gap can be enormous when screening is weak, awareness is low, or primary care is inaccessible.

2. The affordability gap

This is the distance between knowing you are ill and being able to begin treatment. High prices, out of pocket spending, and unstable supply chains widen this gap rapidly.

3. The continuity gap

This is the distance between starting treatment and staying on it long enough to matter. Many health systems can technically deliver an initial prescription but fail at long term adherence because follow up care, refill access, monitoring, and patient support are too costly or too fragmented.

The genius of this framework is that it shifts the question from “How expensive is care?” to “Where exactly are people falling out of the system?” That matters because solutions differ by gap. Screening campaigns help with diagnosis. Price controls, pooled purchasing, and insurance reform help with affordability. Community health programs, refill systems, and chronic care management help with continuity.

If you do not know which gap is largest, you will subsidize the wrong problem.

This is why debates about health care cost often become circular. People argue about prices, insurers, providers, pharmaceuticals, and public budgets as though these were separate issues. They are not. They are all mechanisms that determine whether the three gaps widen or narrow.

In practical terms, a system can be “innovative” and still fail millions if innovation is priced beyond reach. It can also be “low tech” and still save lives if it reliably closes the diagnosis and continuity gaps. The point is not sophistication for its own sake. The point is reach.

The moral mistake of measuring success at the point of invention

Modern health systems often celebrate the moment a drug is invented, approved, or launched. But invention is not the same as impact. A medicine that exists on paper but never reaches the people who need it has not solved the problem it was designed to solve.

This is one of the deepest distortions in health care. We reward the creation of remedies more than the delivery of remedies. We praise the summit and ignore the path. Yet for patients, the path is everything.

Consider what happens when a costly specialty drug enters the market. If it is priced at a level that only wealthy patients, wealthy systems, or highly insured populations can absorb, then access becomes stratified by income, geography, and administrative capacity. A diagnosis no longer means the same thing for everyone. For some, it opens a route to treatment. For others, it opens a door to financial distress.

That is why the real unit of analysis is not the molecule, but the care pathway. Can a person be screened? Can they be diagnosed quickly? Can they begin therapy without ruinous delay? Can they continue taking the medicine? Can they be monitored affordably? If any answer is no, then the system has not really made care available.

There is also a psychological cost to this kind of exclusion. When people learn that treatment exists but is unaffordable, trust erodes. Patients stop believing the system was built for them. Communities become less likely to seek screening, less likely to comply with advice, and less likely to assume that early action will help. Over time, price becomes not just a barrier but a cultural signal that the sick are on their own.

That signal is profoundly corrosive.

Key Takeaways

Do not confuse availability with access. A medicine can exist and still be out of reach if its price, distribution, or monitoring requirements create barriers.
Treat screening as a cost strategy, not a luxury. Early detection of chronic diseases like diabetes prevents far more expensive complications later.
Measure the three gaps. Ask where people are lost: before diagnosis, before treatment, or during long term care.
Focus on reach, not just innovation. The value of a drug is determined by how many people can actually use it, not only by how advanced it is.
Build systems that reduce hidden exclusion. Refill access, primary care, lab testing, and patient follow up are not optional extras. They are the infrastructure of survival.

The real reform is to make illness less isolating

If there is a single lesson connecting expensive health care and widespread undiagnosed disease, it is this: illness becomes most dangerous when it is both common and solitary. Common means many people are affected. Solitary means each person is left to navigate cost, confusion, and fragmentation alone.

That is why the best health systems do not merely invent treatments. They build bridges. They lower the price of entry, find disease earlier, and keep people connected to care long enough for treatment to work. They understand that a diagnosis is not the finish line, and a prescription is not the same thing as a cure.

The question we should ask is not only, “Why is health care so expensive?” It is also, “What kind of society allows a treatable disease to remain invisible until it is costly enough to be seen?” Those are the same question in different forms.

Once you see that, health care pricing stops looking like a narrow economic debate and starts looking like a test of social design. The deepest measure of a health system is not how much it can invent or invoice. It is how close it can bring care to the person who needs it before the disease has time to grow teeth.

That is what affordability really means. Not a discount. Not a subsidy. Distance made shorter.

And in medicine, shorter distance can be the difference between a manageable condition and a life changed forever.